Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study

BACKGROUND: Safinamide is a recent multimodal antiparkinsonian drug that inhibits monoamine oxidase B and modulates the glutamatergic system with positive effects on motor and nonmotor symptoms of Parkinson’s disease (PD). This post-hoc analysis of the European SYNAPSES study provides first-time dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergmans, Bruno, Bourgeois, Philip, Cras, Patrick, Dethy, Sophie, De Klippel, Nina, Franco, Gianni, Garraux, Gaëtan, Geens, Karine, Jacquerye, Philippe, Jeanjean, Anne, Supiot, Frédéric, Van der Linden, Chris, Krygier, Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238295/
https://www.ncbi.nlm.nih.gov/pubmed/36201116
http://dx.doi.org/10.1007/s13760-022-02100-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238295/
https://www.ncbi.nlm.nih.gov/pubmed/36201116
http://dx.doi.org/10.1007/s13760-022-02100-1

Ejemplares similares